Enveric Biosciences, Inc.
ENVB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000890821
No open-market purchases or sales by Enveric Biosciences, Inc. insiders were filed in the last 90 days; 24 institutions reported holding it in 13F filings for Q2 2026, worth $736.8K in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Enveric Biosciences, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- +3 vs. Q4 2023
- Shares held
- 488.5K
- −821 (−0.2%) vs. Q4 2023
- Total value
- $488.4K
- −$147.4K (−23.2%) vs. Q4 2023
- New holders
- 5
- 3 more added
- Sold out
- 2
- 1 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ENVB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 24 | $736.8K |
| Q1 2026 | 11 | $106.6K |
| Q4 2025 | 11 | $87.7K |
| Q3 2025 | 11 | $232.6K |
| Q2 2025 | 14 | $283.2K |
| Q1 2025 | 15 | $344.7K |
| Q4 2024 | 19 | $386.7K |
| Q3 2024 | 17 | $337.2K |
| Q2 2024 | 17 | $307.3K |
| Q1 2024 | 18 | $488.4K |
| Q4 2023 | 15 | $635.8K |
| Q3 2023 | 15 | $518.3K |
| Q2 2023 | 14 | $631.1K |
| Q1 2023 | 13 | $382.4K |
| Q4 2022 | 12 | $356.8K |
| Q3 2022 | 12 | $623.0K |
| Q2 2022 | 27 | $1.99M |
| Q1 2022 | 31 | $3.61M |
| Q4 2021 | 31 | $4.45M |
| Q3 2021 | 24 | $4.64M |
| Q2 2021 | 18 | $2.72M |
| Q1 2021 | 14 | $3.42M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Enveric Biosciences, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| AdvisorShares Investments LLC | 238,833 | $238.8K | 0.04% | +97,000+68.4% | Added |
| HRT Financial LP | 63,026 | $63.0K | 0.00% | +63,026 | New |
| Citadel Advisors LLC | 40,104 | $40.1K | 0.00% | +40,104 | New |
| Virtu Financial LLC | 33,835 | $34.0K | 0.00% | +33,835 | New |
| BlackRock Inc. | 29,578 | $29.6K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 18,247 | $18.2K | 0.00% | +18,247 | New |
| Vanguard Group Inc | 18,198 | $18.2K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 15,397 | $15.4K | 0.00% | +15,397 | New |
| Geode Capital Management, LLC | 13,118 | $13.1K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 12,277 | $12.3K | 0.00% | −397−3.1% | Reduced |
| UBS Group AG | 4,983 | $4.98K | 0.00% | +4,973+49,730.0% | Added |
| Group One Trading, L.P. | 273 | $273 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 150 | $150 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 100 | $100 | 0.00% | 00.0% | Unchanged |
| National Bank of Canada | 70 | $63 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 37 | $37 | 0.00% | +4+12.1% | Added |
| Morgan Stanley | 1 | $1 | 0.00% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 259 | $0 | 0.00% | 00.0% | Unchanged |
| Armistice Capital, LLC | 0 | $0 | 0.00% | −273,000−100.0% | Sold out |
| ORG Partners LLC | 0 | $0 | 0.00% | −10−100.0% | Sold out |